Analysts Set G1 Therapeutics Inc (GTHX) Price Target at $66.00

G1 Therapeutics Inc (NASDAQ:GTHX) has been given a consensus rating of “Buy” by the eleven analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $66.00.

Several equities research analysts have recently weighed in on the company. Wedbush reissued an “outperform” rating and issued a $67.00 price objective on shares of G1 Therapeutics in a report on Friday, March 1st. JPMorgan Chase & Co. downgraded G1 Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $59.00 to $41.00 in a report on Wednesday, January 23rd. Zacks Investment Research upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 12th. BidaskClub upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, February 12th. Finally, B. Riley started coverage on G1 Therapeutics in a research note on Thursday, February 7th. They set a “buy” rating and a $55.00 price target for the company.

Shares of GTHX stock traded down $0.47 during trading hours on Monday, hitting $17.51. The stock had a trading volume of 448,000 shares, compared to its average volume of 301,619. The company has a market capitalization of $672.77 million, a P/E ratio of -6.82 and a beta of 2.32. G1 Therapeutics has a twelve month low of $13.87 and a twelve month high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Thursday, February 28th. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.06). On average, equities research analysts expect that G1 Therapeutics will post -3.05 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC raised its stake in shares of G1 Therapeutics by 6.9% during the fourth quarter. FMR LLC now owns 5,577,754 shares of the company’s stock worth $106,814,000 after purchasing an additional 361,091 shares during the last quarter. BlackRock Inc. raised its position in G1 Therapeutics by 6.9% in the fourth quarter. BlackRock Inc. now owns 1,963,714 shares of the company’s stock worth $37,604,000 after acquiring an additional 126,892 shares in the last quarter. Vanguard Group Inc. raised its position in G1 Therapeutics by 76.3% in the third quarter. Vanguard Group Inc. now owns 1,717,733 shares of the company’s stock worth $89,821,000 after acquiring an additional 743,596 shares in the last quarter. Vanguard Group Inc raised its position in G1 Therapeutics by 76.3% in the third quarter. Vanguard Group Inc now owns 1,717,733 shares of the company’s stock worth $89,821,000 after acquiring an additional 743,596 shares in the last quarter. Finally, Capital World Investors raised its position in G1 Therapeutics by 19.9% in the third quarter. Capital World Investors now owns 1,215,000 shares of the company’s stock worth $63,532,000 after acquiring an additional 202,000 shares in the last quarter. Institutional investors and hedge funds own 75.08% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Read More: Catch-Up Contributions

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.